Savings from the introduction of BPaL and BPaLM regimens at the country level
BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB.SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from cestrum orange peel current s